Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 6/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211395 | 1.00 | HDAC1 (0.61) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL4209044 | 0.92 | HDAC1 (0.73) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL4209055 | 0.92 | HDAC1 (0.73) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL211458 | 0.92 | HDAC1 (0.60) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL211459 | 0.92 | HDAC1 (0.60) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL13529796 | 0.90 | HDAC1 (0.48) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL13970536 | 0.87 | HDAC1 (0.53) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL209583 | 0.86 | HDAC1 (0.58) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL209584 | 0.86 | HDAC1 (0.58) | HDAC1KCNH2HDAC3HDAC4HDAC7 | |
| SCHEMBL12660519 | 0.85 | HDAC1 (0.79) | HDAC1KCNH2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735319-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2017-05-03 | — | — | EP | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7402603-B2 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2008-07-22 | — | — | US | disclosed |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | disclosed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | disclosed |
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040067540-A1 | Rapid method for screening compounds for in vivo activity | LASSOTA PIOTR (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | disclosed |
| EP-1364206-A2 | RAPID METHOD FOR SCREENING COMPOUNDS FOR IN VIVO ACTIVITY | Novartis AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | disclosed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002055742-A2 | RAPID METHOD FOR SCREENING COMPOUNDS FOR IN VIVO ACTIVITY | NOVARTIS AG (CH) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | HDAC1 3/4885KCNH2 4396/4885HDAC3 5/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885KCNH2 4577/4885HDAC3 2/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885KCNH2 4577/4885HDAC3 2/4885 |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885KCNH2 2831/4885HDAC3 1/4885 |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | HDAC1 3/4885KCNH2 4396/4885HDAC3 5/4885 |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | HDAC2, HDAC9, HDAC1 | HDAC1 3/4885KCNH2 4396/4885HDAC3 5/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885KCNH2 4577/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.